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In addition to skeletal muscle and the nervous system,
a-dystroglycan is found in the podocyte basal membrane,
stabilizing these cells on the glomerular basement
membrane. Fukutin, named after the gene responsible for
Fukuyama-type congenital muscular dystrophy, is a putative
glycosyltransferase required for the post-translational
modification of a-dystroglycan. Chimeric mice targeted for
both alleles of fukutin develop severe muscular dystrophy;
however, these mice do not have proteinuria. Despite the
lack of a functional renal defect, we evaluated glomerular
structure and found minor abnormalities in the chimeric mice
by light microscopy. Electron microscopy revealed flattening
of podocyte foot processes, the number of which was
significantly lower in the chimeric compared to wild-type
mice. A monoclonal antibody against the laminin-binding
carbohydrate residues of a-dystroglycan did not detect
a-dystroglycan glycosylation in the glomeruli by
immunoblotting or immunohistochemistry. In contrast,
expression of the core a-dystroglycan protein was preserved.
There was no statistical difference in dystroglycan mRNA
expression or in the amount of nephrin and a3-integrin
protein in the chimeric compared to the wild-type mice
as judged by immunohistochemistry and real-time RT-PCR.
Thus, our results indicate that appropriate glycosylation of
a-dystroglycan has an important role in the maintenance of
podocyte architecture.
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Podocytes are highly differentiated cells that possess specia-
lized projections called foot processes. Adhesion molecules of
podocytes are likely to have an important role in the
maintenance of podocyte morphology by anchoring of these
cells to the glomerular basement membrane (GBM).1,2 To
date, two major adhesion protein systems have been
identified. As the first step, a3b1-integrin was localized
exclusively to the podocyte basal membrane domains in
normal and flattened human podocytes and was speculated
to contribute to the firm adhesion of the podocytes to the
GBM matrix proteins.3–5
Recently, a- and b-dystroglycans were discovered in
podocytes, and were found to be localized to the podocytes
basal membrane domain.6,7 Dystroglycan is composed of a
transmembrane, heterodimeric complex of a- and b-subunits
that link the extracellular matrix to the cell cytoskeleton.
Gene knockout experiments have not been helpful for
understanding the role of dystroglycans in podocyte func-
tion, because knockout results in early embryonic death, long
before kidney glomeruli develop, and because Reichert’s
membrane, the first canonical basement membrane produced
by the embryo, is disorganized, and it fails to withstand the
blood pressure of maternal circulation.8
Fukuyama-type congenital muscular dystrophy (FCMD),
discovered in Japan, is a severe muscular dystrophy with
central nervous system involvement.9 Fukutin, named after
the gene responsible for FCMD, is a putative glycosyltrans-
ferase required for post-translational modification of
a-dystroglycan.10,11
Chimeric mice generated using embryonic stem cells
targeted for both fukutin alleles develop severe muscular
dystrophy associated with the defective glycosylation of a-
dystroglycan.12 In this study, we investigated fukutin-
deficient chimeric mice to clarify the role of a-dystroglycan
glycosylation for maintaining podocyte architecture.
RESULTS
Chimeric mice showed muscle weakness, were unable to walk
in a straight line, and dragged their feet as previously
described.12
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Light microscopy of kidney specimens showed minor
abnormalities (Figure 1) together without massive albumi-
nuria. Electron microscopy revealed morphological changes
in podocytes such as vacuolization, microvillous transforma-
tion, and segmental foot process effacement. However,
the detachment of foot processes from the GBM was not
observed (Figure 2). The number of foot processes along the
GBM decreased significantly in chimeric mice (1.39±
0.18/ mm GBM; Figure 3b) compared with wild-type mice
(2.09±0.01/mm GBM; Figure 3a) (P¼ 0.039; Figure 3c). In
addition, the GBM was thickened and the three-layered
structure of the GBM was lost under the lesion of flattened
foot processes in chimeric mice (Figure 3b). The thickness
of the GBM was increased significantly in chimeric mice
(0.30±0.03 mm) compared with wild-type mice (0.15±
0.01 mm) (P¼ 0.043; Figure 3d).
Immunohistochemistry using the IIH6 monoclonal anti-
body against the laminin-binding carbohydrate residues of
a-dystroglycan (Figure 4a) and rabbit polyclonal antibody
AP1530 against the 34 amino acids in the C-terminal domain
of human a-dystroglycan indicated that the a-dystroglycan
was localized along the glomerular capillary walls in a linear
manner in wild-type mice kidneys (Figure 4c). In contrast,
the expression of a-dystroglycan laminin-binding carbo-
hydrate residues decreased in chimeric mice (Figure 4b).
Immunohistochemistry revealed that expression of the core
a-dystroglycan protein was relatively preserved in chimeric
mice (Figure 4d).
In wild-type mice, immunoblotting detected a broad band
around 150 kDa representing a-dystroglycan (Figure 4e).
Expression of laminin-binding carbohydrate residues was
reduced in chimeric mice (Figure 4e), whereas that of the core
a-dystroglycan protein was relatively preserved in chimeric
mice. An additional band around 75 kDa was detected
in chimeric mice, suggesting that considerable parts of
a-dystroglycan were hypoglycosylated (Figure 4f). There was
no statistical difference in the mRNA expression of dystrogly-
can between the wild-type and chimeric mice (Figure 4g).
In wild-type mice, a laminin overlay assay detected a broad
band around 150 kDa corresponding to a-dystroglycan, whereas
the overlay assay revealed a deficiency in the laminin-binding
activity of a-dystroglycan in chimeric mice (Figure 4h).
The expression of a3-integrin (another adhesion molecule
localized to the podocytes basal membrane domain) and
nephrin (which is thought to be the main component of the
slit diaphragm)13 was also investigated. The expression levels
of a3-integrin and nephrin were unaltered in chimeric
mice using immunohistochemistry and real-time RT-PCR
(Figure 5a–d, g, and h).
Tetramethylrhodamine (TRITC)-conjugated wheat germ
agglutinin (WGA) staining was performed to detect sialic acid
and N-acetyl-glucosamine (GlcNAc) oligomer. WGA staining
was observed along the glomerular capillary walls in a linear
manner in wild-type mice. Similar staining was observed in
chimeric mice, suggesting that fukutin deficiency did not affect
GlcNAc oligomers and sialic acid (Figure 5e and f).
DISCUSSION
Dystroglycan is expressed in many cell types such as skeletal
muscles, various epithelia, and in the nervous system.14,15
a-Dystroglycan is heavily glycosylated by O-mannosyl
glycosylation. It is speculated that a-dystroglycan carbohy-
drate residues are bound to the cationic LG domain common
to several matrix proteins such as laminin and agrin.16 In
the glomerulus, a-dystroglycan is localized to basal cell
membrane domains of the podocyte, stabilizes podocytes on
the GBM, and presumably is involved in the pathogenesis of
foot process flattening.17
Using the IIH6 monoclonal antibody, we found that the
expression of a-dystroglycan laminin-binding carbohydrate
residues decreased in fukutin-deficient chimeric mice,
whereas expression of the core a-dystroglycan protein was
preserved. These results confirmed that fukutin is involved in
the modification of a-dystroglycan laminin-binding carbo-
hydrate residues. We performed the laminin blot overlay
assay to evaluate the binding activity of a-dystroglycan to
laminin and revealed a severe reduction in the binding
a b
Figure 1 |Photomicrographs of periodic acid Schiff stain.
Representative photomicrographs of wild-type (a) and the
fukutin-deficient chimeric mice (b). Glomeruli from the fukutin-
deficient chimeric mice have no abnormalities by light
microscopy. Original magnification  200.
Figure 2 |Transmitted electron photomicrograph of the
fukutin-deficient chimeric mice. The flattening of foot processes
was observed in segmental lesion of capillary lumens (arrowheads).
No detachment of foot processes from the GBM was observed.
Original magnification  4000. GBM, glomerular basement
membrane.
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activity in chimeric mice. Previously we reported that injury
to a-dystroglycan with reactive oxygen species or protamine
sulfate directly split the attachments of a-dystroglycan to
laminin and agrin, and this led to the induction of foot
process flattening.17 Similar results were also found that for
deglycosylated a-dystroglycan by reactive oxygen species, which
led to impaired binding to laminin and agrin, and to foot
process flattening.18 These data suggest that defective glycosyla-
tion of a-dystroglycan causes inhibition of binding to laminin
and agrin resulting in the flattening of foot processes.
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Figure 4 |Defective glycosylation of a-dystroglycan decreases the binding activity to laminin. Immunohistochemistry (a–d) and
immunoblotting (e, f) reveal reduction of the laminin-binding carbohydrate residues of a-dystroglycan (a, b, e) in the chimeric mice
(chimera) compared with the wild-type mice (wild-type). Expression of core protein of a-dystroglycan (c, d, f) is relatively preserved in the
chimeric mice (chimera). The additional band around 75 kDa is detected in the chimeric mice, suggesting considerable parts of
a-dystroglycan are hypoglycosylated (f). (g) Expression of dystroglycan by real-time RT-PCR in the wild-type mice (wild-type) and
the chimeric mice (chimera). (h) Laminin binding activity of a-dystroglycan. Blot overlay analysis shows that the binding activity of
a-dystroglycan is decreased in the chimeric mice (chimera). NS, not significant
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Figure 3 |The number of foot processes and the thickness of the GBM. Representative transmitted electron photomicrographs of wild-
type (a) and the fukutin-deficient chimeric mice (b). The GBM under the foot process effacement is thickened and the three-layered
structure is lost. The number of foot processes per mm GBM (c) and the thickness of the GBM (d) in wild-type mice (wild-type) and the
chimeric mice (chimera). Values are expressed as means±s.d. #Po0.05 vs wild type. GBM, glomerular basement membrane.
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The podocyte structure was changed in the fukutin-
deficient chimeric mice. However, there was no detachment
of foot processes from the GBM. The expression of
a3-integrin (another adhesion molecule localized to the
podocyte basal membrane domain) was preserved in
chimeric mice. Kitsiou et al.19 found that anti-a3-integrin
monoclonal antibody decreased the adhesion of human
podocytes to collagen type IV. Homozygous mutant mice
with targeted knockout of a3-integrin fail to form complete
foot processes resulting in podocyte detachment.20 The
presence of a3-integrin in chimeric mice might rescue the
detachment of podocytes from the GBM.
WGA lectin staining was performed to detect sialic acid
and GlcNAc oligomer in the glomerular capillaries. Sialic
acid residues on podocalyxin and other glycoproteins are
essential for maintenance of podocyte architecture.21,22
Defect of heparan sulfate glycosaminoglycan containing
GlcNAc oligomer is shown to induce foot process effacement
without severe proteinuria.23 WGA staining was retained
in chimeric mice, suggesting that fukutin deficiency was
not affecting glycosylation of other glycoproteins except for
a-dystroglycan.
It is interesting to note that urinary protein excretion did
not increase in chimeric mice despite the flattening of foot
processes. One reason for this phenomenon may be that the
degree of foot process effacement was not extensive.
Furthermore, the expressions of a3-integrin and nephrin
were relatively preserved in chimeric mice. We reported
decreased a3-integrin expression and foot process effacement,
which precedes the development of proteinuria, in puromy-
cin aminonucleoside nephrosis.5 In this study, the retained
a3-integrin might contribute to the prevention of proteinuria
in chimeric mice. Nephrin, a member of the Ig superfamily,
was first discovered as one of the slit diaphragm proteins.13
Mutations in nephrin lead to a loss of normal podocyte
structure, resulting in fetal proteinuria in congenital
nephrotic syndrome of the Finnish type.24,25 Some investi-
gators have reported that nephrin expression is lower in
patients with primary acquired nephrotic syndrome.26,27 In
this study, preserved a3-integrin and nephrin might have
prevented proteinuria in chimeric mice.
So far, no information is available concerning glomerular
changes in FCMD in the literature, because these patients
usually do not develop proteinuria. Most patients with
FCMD develop serious muscle weakness, global develop-
mental delay, and die by 20 years of age.9 The lack of long-
term survival might disturb development of proteinuria in
FCMD patients. However, the possibility that foot process
effacement occurs subtly in these patients during their
infantile periods cannot be ruled out.
A generalized gene knockout of dystroglycan results in
early embryonic death before the development of renal
glomeruli8 because the Reichiert’s membrane matrix proteins
are disorganized. Fukutin homozygous-null mice also cannot
survive beyond an early embryonic stage because of the
fragility of the basement membranes.28 An example of
dystroglycan function is observed in skeletal muscle cells
where it mediates the redistribution of matrix proteins under
the control of the actin cytoskeleton, and vice versa.29 High-
resolution electron microscopy showed that arrays of fibers in
the lamina rara externa are irregularly arranged in puromycin
aminonucleoside nephrosis and after protamine sulfate
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Figure 5 | Expression of a3-integrin or nephrin, and WGA lectin staining. Immunohistochemistry (a–d) and real-time RT-PCR (g, h) for
a3-integrin (a, b, g) or nephrin (c, d, h), and TRITC-conjugated WGA lectin staining (e, f) in the wild-type mice (wild-type) or the chimeric
mice (chimera). Expressions of a3-integrin and nephrin are preserved in the chimeric mice (b, d). WGA staining is localized along the
glomerular capillary walls in wild-type (e) and chimera (f). NS, not significant; TRITC, tetramethylrhodamine; WGA, wheat germ agglutinin.
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perfusion.17 Similar to that study, this study showed that
chimeric mice had a significant increase in the thickness of
the GBM with a loss of its three-layered structure. These
findings imply that a-dystroglycan is important for organiz-
ing extracellular matrix proteins and forming a stable
basement membrane structure in the glomerulus.
In conclusion, the results of this study indicate that
appropriate glycosylation of a-dystroglycan may be impor-
tant in the maintenance of podocyte architecture and
matrix assembly in the GBM. Further investigation into the
relationships of slit membrane-related molecules, cytoskeletal
proteins, and adhesion molecules is essential to clarify the
mechanisms of proteinuria.
MATERIALS AND METHODS
Antibodies and lectin
Mouse monoclonal antibodies against laminin-binding carbohy-
drate residues of a-dystroglycan (IIH6) were obtained from Upstate
Biotechnology (Lake Placid, NY). Rabbit anti-laminin antibody
was purchased from Sigma Chemical (St Louis, MO). Rabbit
anti-human a3-integrin polyclonal antiserum was obtained from
Chemicon International (Temecula, CA). Preparations of rabbit
polyclonal antibody against the 34 amino acids in the C-terminal
domain of human a-dystroglycan (AP1530) and anti-nephrin
antibody were described previously.30,31 fluorescein isothiocyanate-
or horseradish peroxidase-conjugated secondary antibodies were
obtained from Dako (Glostrup, Denmark). TRITC-conjugated
WGA was obtained from Vector Laboratories (Burlingame, PA).
Animals
Fukutin-deficient chimeric mice were generated using embryonic
stem cells targeted for both fukutin alleles (n¼ 3) as previously
reported.12 C57BL/6 mice were used as normal controls (n¼ 3).
Mice were killed at 7 months of age. All animal experiments were
approved by the local ethics committee.
Urinary albumin excretion was determined using Albustix (Bayer
Medical, Tokyo, Japan).
Light microscopy, immunochemistry, and lectin
histochemistry
Renal cortices were fixed in 4% paraformaldehyde, embedded in
paraffin, and 4 mm-thick sections were cut. Sections were stained
with Periodic acid-Schiff reaction.
Frozen sections (4-mm thick) were cut and stained using the
indirect immunofluorescence method. TRITC-conjugated WGA
staining was performed according to the manufacturer’s instructions.
Electron microscopy
The fixed renal cortices were embedded in epoxy resin using
conventional methods. Ultrathin sections were prepared, stained
with uranyl acetate and lead citrate, and were then examined with a
JEOL 1200EX electron microscope (JEOL, Tokyo, Japan). To
evaluate the morphological changes in podocytes, the number of
epithelial foot processes per mm of GBM and thickness of GBM were
calculated using a curvimeter. Three glomeruli were randomly
selected from each mouse and 10 electron micrographs were taken
in each glomerulus. Areas of wrinkled GBM were excluded. The
measurements were taken from electron micrographs with magni-
fications of  10,000.
Immunoblotting
Mouse kidney cortices were extracted with RIPA buffer (20mM
Tris-HCl, 150mM NaCl, 2mM EDTA, 1% Nonidet P-40, 1% sodium
deoxycholate, 0.1% SDS) for 2 h at 4 1C, followed by centrifugation
at 500 g for 5min. The supernatants were dissolved in SDS sample
buffer and electrophoresed on 7.5% polyacrylamide gels under
reducing conditions. Gels loaded with samples were transferred onto
nitrocellulose membranes (Amersham Pharmacia Biotech, Uppsala,
Sweden). Immunoblotting was performed with the primary
antibodies, and detection was performed with an enhanced chemi-
luminescence kit (Amersham Pharmacia Biotech).
Blot overlay analysis
The nitrocellulose transfers of renal cortex lysates were blocked in
10mM Tris-HCl (pH 7.6), 140mM NaCl, 1mM CaCl2, and 1mM
MgCl2 (LBB) containing 5% non-fat dry milk for 1 h at room
temperature. The transfers were incubated with LBB containing
0.1–0.5mg per stripe EHS laminin (Koken, Tokyo, Japan) overnight
at 4 1C. Bound laminin was detected using anti-laminin anti-
body and the development was conducted with an enhanced
chemiluminescence kit (Amersham).
Real-time RT-PCR
RNA was isolated from renal tissues using TRIzol reagent
(Invitrogen, Paisley, UK) according to the manufacturer’s instruc-
tions. Total RNA (1 mg) was used as a template. Real-time RT-PCR
was performed using the LightCycler FastStart kit with SYBR Green
(Roche Molecular Systems, Alameda, CA). Reaction conditions were
as follows: an initial hold at 50 1C for 10min followed by 95 1C for
5min to achieve first-strand synthesis. PCR was cycled for 40
iterations; 95 1C for 10 s, 55 1C for 30 s, and 72 1C for 1min. The
Reaction was completed at 72 1C for 10min. The primer pairs
used were: a3b1-integrin (forward, TCCGTGGACATCGACTCTGA;
reverse, AGCTTCATACAGGGCACGAG), dystroglycan (forward,
GGACCCTGAGAAGAGCAGTG; reverse, TGGTAGGGAGGTGCAT
TAGG), nephrin (forward, GATCCAGGTCTCCGTCACTA; reverse,
GAAGACCACCAACTGCAAAG). The transcript level in the wild-
type was arbitrarily expressed as 1.
Statistics
All data are expressed as means±s.d. Values were analyzed by
unpaired Student’s t-test. Po0.05 was considered significant.
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